Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention

Deepak L. Bhatt; A. Michael Lincoff; Dean J. Kereiakes; James E. Tcheng; Maarten L. Simoons; L. Ron Van Der Wieken; Nikki Godfrey; Robert M. Califf; Eric J. Topol

doi:10.1016/S0002-9149(98)00565-7

Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention

Deepak L. Bhatt
, A. Michael Lincoff
, Dean J. Kereiakes
, James E. Tcheng
, Maarten L. Simoons
, L. Ron Van Der Wieken
, Nikki Godfrey
, Robert M. Califf
, Eric J. Topol

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Data from the 5 large randomized, double-blind, placebo-controlled trials that used glycoprotein IIb/IIIa inhibitors during percutaneous transluminal coronary angioplasty were pooled for a total of 10,691 patients. We found that the use of glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions significantly decreases the need for unplanned stenting for abrupt closure.

Original language	English
Pages (from-to)	1105-1106
Number of pages	2
Journal	American Journal of Cardiology
Volume	82
Issue number	9
DOIs	https://doi.org/10.1016/S0002-9149(98)00565-7
State	Published - 1998

Access to Document

10.1016/S0002-9149(98)00565-7

Cite this

Bhatt, D. L., Lincoff, A. M., Kereiakes, D. J., Tcheng, J. E., Simoons, M. L., Van Der Wieken, L. R., Godfrey, N., Califf, R. M., & Topol, E. J. (1998). Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention. American Journal of Cardiology, 82(9), 1105-1106. https://doi.org/10.1016/S0002-9149(98)00565-7

@article{10e2f5ff26ca4f86a18c27c3be5bb114,

title = "Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention",

abstract = "Data from the 5 large randomized, double-blind, placebo-controlled trials that used glycoprotein IIb/IIIa inhibitors during percutaneous transluminal coronary angioplasty were pooled for a total of 10,691 patients. We found that the use of glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions significantly decreases the need for unplanned stenting for abrupt closure.",

author = "Bhatt, \{Deepak L.\} and Lincoff, \{A. Michael\} and Kereiakes, \{Dean J.\} and Tcheng, \{James E.\} and Simoons, \{Maarten L.\} and \{Van Der Wieken\}, \{L. Ron\} and Nikki Godfrey and Califf, \{Robert M.\} and Topol, \{Eric J.\}",

year = "1998",

doi = "10.1016/S0002-9149(98)00565-7",

language = "English",

volume = "82",

pages = "1105--1106",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "9",

}

Bhatt, DL, Lincoff, AM, Kereiakes, DJ, Tcheng, JE, Simoons, ML, Van Der Wieken, LR, Godfrey, N, Califf, RM & Topol, EJ 1998, 'Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention', American Journal of Cardiology, vol. 82, no. 9, pp. 1105-1106. https://doi.org/10.1016/S0002-9149(98)00565-7

TY - JOUR

T1 - Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention

AU - Bhatt, Deepak L.

AU - Lincoff, A. Michael

AU - Kereiakes, Dean J.

AU - Tcheng, James E.

AU - Simoons, Maarten L.

AU - Van Der Wieken, L. Ron

AU - Godfrey, Nikki

AU - Califf, Robert M.

AU - Topol, Eric J.

PY - 1998

Y1 - 1998

N2 - Data from the 5 large randomized, double-blind, placebo-controlled trials that used glycoprotein IIb/IIIa inhibitors during percutaneous transluminal coronary angioplasty were pooled for a total of 10,691 patients. We found that the use of glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions significantly decreases the need for unplanned stenting for abrupt closure.

AB - Data from the 5 large randomized, double-blind, placebo-controlled trials that used glycoprotein IIb/IIIa inhibitors during percutaneous transluminal coronary angioplasty were pooled for a total of 10,691 patients. We found that the use of glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions significantly decreases the need for unplanned stenting for abrupt closure.

UR - https://www.scopus.com/pages/publications/0031790932

U2 - 10.1016/S0002-9149(98)00565-7

DO - 10.1016/S0002-9149(98)00565-7

M3 - Article

C2 - 9817488

AN - SCOPUS:0031790932

SN - 0002-9149

VL - 82

SP - 1105

EP - 1106

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 9

ER -

Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention

Abstract

Access to Document

Fingerprint

Cite this